GGrantIndex
← Leaderboards

Leo L Cheng

Massachusetts General Hospital

$11,540,322
Attributed
$13,113,700
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200523
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$13,113,700 · 10

By mechanism

R01$10,548,152 · 4
R21$1,523,684 · 4
S10$600,000 · 1
R29$441,864 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Magnetic Resonance Spectroscopy

Research focus

Magnetic Resonance SpectroscopyTissuesMetabolicSuccessMalignant NeoplasmsBaseEvaluationClinicProtocols DocumentationHistopathologyProstateTumorSerumMalignant Neoplasm Of ProstateBiologicalCancer PatientOperative Surgical ProceduresDiagnosisSamplingMetabolomicsEarly DiagnosisStagingBiochemicalAdjuvant Therapy

Grant awards (33)

Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuli$786,689
R01 · FY2023 · AG · contact PI
Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuli$786,689
R01 · FY2022 · AG · contact PI
Novel metabolomic contrast probes for human lung cancer characterization$682,367
R01 · FY2022 · CA · contact PI
Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuli$786,689
R01 · FY2021 · AG · contact PI
Identification of prostate cancer aggressiveness using hyperpolarized polyamine metabolic rates$184,099
R21 · FY2020 · CA · contact PI
Identification of prostate cancer aggressiveness using hyperpolarized polyamine metabolic rates$251,698
R21 · FY2019 · CA · contact PI
Upgrade of Console for 600 MHz MR Spectrometer$600,000
S10 · FY2017 · OD · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$556,388
R01 · FY2017 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$556,388
R01 · FY2016 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$556,388
R01 · FY2015 · CA · contact PI
Characterizing Prostate Cancer by ex vivo MRS Signature(AdminSupp)$192,743
R01 · FY2015 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$550,018
R01 · FY2014 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$576,016
R01 · FY2013 · CA · contact PI
Development of Metabolomic and Molecular Probes for Prostate Cancer Assessment$189,315
R21 · FY2012 · CA · contact PI
Development of Metabolomic and Molecular Probes for Prostate Cancer Assessment$228,593
R21 · FY2011 · CA · contact PI
Detection of Lung Cancer Risks for Serum Metabolomics$184,153
R21 · FY2011 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$557,308
R01 · FY2010 · CA · contact PI
Detection of Lung Cancer Risks for Serum Metabolomics$247,666
R21 · FY2010 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$564,008
R01 · FY2009 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$535,894
R01 · FY2009 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$552,364
R01 · FY2008 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$566,537
R01 · FY2007 · CA · contact PI
Characterizing Prostate Cancer By ex vivo MRS Signatures$597,974
R01 · FY2006 · CA · contact PI
Defining Signatures of Breast Cancer Cells by HRMAS MRS$280,853
R01 · FY2006 · CA · contact PI
Defining Signatures of Breast Cancer Cells by HRMAS MRS$287,613
R01 · FY2005 · CA
Defining Signatures of Breast Cancer Cells by HRMAS MRS$287,613
R01 · FY2004 · CA
Defining Signatures of Breast Cancer Cells by HRMAS MRS$287,613
R01 · FY2003 · CA
EVALUATION OF ASTROCYTOMAS WITH HRMAS 1HMR SPECTROSCOPY$92,853
R29 · FY2003 · CA
EVALUATION OF ASTROCYTOMAS WITH HRMAS 1HMR SPECTROSCOPY$89,775
R29 · FY2002 · CA
CHARACTERIZATION OF PROSTATE CANCER WITH HRMAS 1HMRS$120,260
R21 · FY2001 · CA
EVALUATION OF ASTROCYTOMAS WITH HRMAS 1HMR SPECTROSCOPY$119,700
R29 · FY2001 · CA
EVALUATION OF ASTROCYTOMAS WITH HRMAS 1HMR SPECTROSCOPY$139,536
R29 · FY2000 · CA
CHARACTERIZATION OF PROSTATE CANCER WITH HRMAS 1HMRS$117,900
R21 · FY2000 · CA